Other equities research analysts also recently issued research reports about the company. BidaskClub downgraded Kura Oncology from a hold rating to a sell rating in a report on Thursday, December 7th. Zacks Investment Research downgraded Kura Oncology from a buy rating to a hold rating in a report on Thursday, March 22nd. ValuEngine upgraded Kura Oncology from a sell rating to a hold rating in a report on Monday, April 2nd. Wedbush assumed coverage on Kura Oncology in a report on Tuesday, December 26th. They set a buy rating and a $19.00 price target for the company. Finally, Oppenheimer set a $18.00 price target on Kura Oncology and gave the stock a buy rating in a report on Monday, December 11th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $22.00.
NASDAQ KURA opened at $16.70 on Thursday. Kura Oncology has a 52 week low of $5.90 and a 52 week high of $24.02. The company has a current ratio of 9.44, a quick ratio of 9.44 and a debt-to-equity ratio of 0.07.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its holdings in Kura Oncology by 49.1% during the fourth quarter. BlackRock Inc. now owns 1,524,817 shares of the company’s stock worth $23,331,000 after buying an additional 502,296 shares in the last quarter. Nexthera Capital LP grew its holdings in Kura Oncology by 72.3% during the fourth quarter. Nexthera Capital LP now owns 445,550 shares of the company’s stock worth $6,817,000 after buying an additional 187,034 shares in the last quarter. Millennium Management LLC grew its holdings in Kura Oncology by 35.7% during the fourth quarter. Millennium Management LLC now owns 303,905 shares of the company’s stock worth $4,650,000 after buying an additional 79,989 shares in the last quarter. Geode Capital Management LLC grew its holdings in Kura Oncology by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 166,914 shares of the company’s stock worth $2,553,000 after buying an additional 3,255 shares in the last quarter. Finally, State Street Corp bought a new stake in Kura Oncology during the second quarter worth $1,394,000. Institutional investors and hedge funds own 58.56% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.